Can diabetics use Wegovy, and is it suitable for your type?

You have type 2 diabetes and want to lose weight — here is where Wegovy fits

Imagine you were diagnosed with type 2 diabetes several years ago, you have been managing it with metformin or another oral medicine, and your GP has mentioned that losing weight would improve your blood sugar control significantly. You have heard about Wegovy and wondered whether the same medicine being used for weight loss could work for you. The good news is that semaglutide, the active ingredient in Wegovy, has been studied specifically in people with type 2 diabetes in the STEP 2 trial, and the results were meaningful: participants lost around 10% of body weight on average over 68 weeks, alongside reductions in HbA1c. That is a smaller average than in people without diabetes, but the metabolic benefit stacks up.

Wegovy itself is licensed for weight management in adults with a BMI of 30 or above, or 27 and above alongside a weight-related health condition — and type 2 diabetes qualifies as one of those conditions. So eligibility on paper exists. The clinical question a prescriber needs to answer is whether Wegovy fits safely alongside whatever you are already taking. Sulphonylureas and insulin, for instance, lower blood sugar independently; adding a GLP-1 medicine can increase the risk of hypoglycaemia, so dose adjustments to existing medicines may be needed. That conversation happens with your prescriber, not before one. You can read more about how semaglutide works for weight management on our Wegovy overview page.

One thing worth clearing up: Ozempic, which is also semaglutide, is licensed for type 2 diabetes at lower doses. Wegovy is the weight-management version at 2.4mg. They are not interchangeable on a prescription, and Ozempic should not be sought for weight loss. The detailed guide for people with type 2 diabetes goes further on what to discuss with your doctor.

Type 1 diabetes and Wegovy: what the evidence does and does not support

The situation for type 1 diabetes is different, and it is important to be direct about that. Wegovy is not licensed for type 1 diabetes. It has not been through the same clinical trial programme for this group, and there is a common assumption that because semaglutide helps blood sugar in type 2 diabetes, it must be similarly helpful in type 1. That assumption does not hold cleanly. People with type 1 diabetes rely on insulin for survival, and GLP-1 receptor agonists do not replace insulin or reliably predict how insulin requirements will shift. The risk of hypoglycaemia and the complexity of managing that on a titrating GLP-1 medicine means this is specialist territory.

That is not to say research has ignored the question entirely. Some small studies have explored semaglutide in type 1 diabetes, mostly in people who also have obesity, and results have been cautiously interesting. But cautiously interesting in a research context is not the same as a licensed, established treatment pathway. Any prescriber considering this off-label would need to be doing so within specialist endocrinology or diabetes care, with close monitoring in place. Our page covering Wegovy and type 1 diabetes outlines the current clinical picture in more detail.

If you have type 1 diabetes and obesity and feel your weight is affecting your health, the right first step is a conversation with your diabetes specialist team. They can consider the full picture, including whether any weight-management medicine is appropriate and under what conditions. Do not start or stop any diabetes medicines without that guidance.

Hypoglycaemia, monitoring, and what a clinical review actually checks

One thing a prescriber will look at carefully when diabetes is in the picture is your current HbA1c, which medicines you take, whether you self-monitor your blood glucose, and how well-controlled your diabetes currently is. These are not tick-box questions; they shape whether semaglutide is safe to introduce and at what pace. Wegovy is started at 0.25mg and titrated gradually over several months up to the 2.4mg maintenance dose. During that period, if you are on insulin or a sulphonylurea, your blood sugar responses may shift and your existing doses may need to come down. That is not a complication; it is an expected and manageable effect that needs oversight.

The MHRA's guidance on GLP-1 medicines for people with diabetes emphasises the importance of not adjusting existing diabetes medicines without medical advice, and of being alert to hypoglycaemia symptoms if you are on any medicine that already lowers blood sugar. The NHS medicines information for semaglutide covers what to watch for. Separately, Wegovy is also subject to an ongoing MHRA Drug Safety Update programme; the January 2026 update flagged acute pancreatitis as an infrequent but serious risk across GLP-1 medicines, with severe stomach pain radiating to the back as the key warning sign to act on immediately. This applies to everyone on these medicines, diabetes or not.

A prescriber at a regulated service like ours will review your full health history, including your diabetes status and current treatment, before any prescription is issued. If Wegovy is not appropriate, that will be the outcome of the consultation. If it is, treatment can move forward with proper aftercare in place. You can also explore whether Wegovy for weight loss is an option for people with diabetes as a starting point.

How to find the right route forward

The clearest path depends on which diabetes type you have, how it is currently managed, and what you are hoping to achieve. For most people with type 2 diabetes and a qualifying BMI, the licensed eligibility criteria for Wegovy do include them, and semaglutide has a strong evidence base in this group. The clinical question is whether it sits safely alongside your existing treatment. For people with type 1 diabetes, the honest answer is that this needs specialist input and is not a decision a private weight-management service should take alone.

If you are unsure whether you fall within the NHS criteria for weight-management medicines, the NICE guidance on semaglutide (TA875) sets out who qualifies for NHS treatment. NHS pathways for Wegovy currently route through specialist weight management services, where waiting lists can be long. Private prescription through a GPhC-registered pharmacy is a separate, parallel route for those who are eligible clinically but prefer not to wait. Our consultation page is where that process begins: a prescriber reviews your health history personally, and if Wegovy is not the right option for your situation, that is what you will be told. No pressure; just a clinical answer.

If cost is part of your thinking, the UK cost context for Wegovy is worth reading before you start comparing providers. And if you have questions about potential side effects, heartburn and digestive effects are among the most commonly raised by people starting treatment.